February 13, 2017
Fitch Even partner Kendrew H. Colton was quoted in an article published in this week’s issue of Chemical & Engineering News, a publication of the American Chemical Society.
The article, titled "Dispute Over the Legal Rights to an Anticancer Agent Continues," discusses the ongoing dispute between Scripps Research Institute California and Oncoceutics, Inc., a clinical-stage drug discovery and development company, involving the patent for an anticancer agent.
Ken has been practicing intellectual property law for over 30 years. His primary practice focus is counseling clients on a wide range of IP matters involving established and emerging chemical and biochemical technologies. Ken has been a member of the Chemical & Engineering News Advisory Board since 2012.
IP Alert | Knowledge Within the Art Does Not Save Means-Plus-Function Claim Term Lacking Corresponding StructureFebruary 19, 2021
On February 12, in Synchronoss Technologies, Inc. v. Dropbox, Inc., the Federal Circuit affirmed that certain of Synchronoss's claims were invalid for indefiniteness, since the claims included a means-plus-function claim term that did not have adequate structural support in the specification. Read more
IP Alert | Customer Loyalty Program Does Not Claim Patent-Eligible Subject MatterFebruary 16, 2021
On February 8, in cxLoyalty, Inc v. Maritz Holdings, Inc., the Federal Circuit invalidated a patent for failure to claim patentable subject matter, reversing findings of the PTAB relating to substitute claims in a CBM review. Read more